Recently, Shenzhen Beimei Pharmaceutical Co., Ltd. (hereinafter referred to as "Beimei Pharma") has completed a new financing round with investors including Jiangsu Jinqiao Private Equity Fund Management Co., Ltd., Nanshan SEI Investment and Jiangsu Aosaikang Pharmaceutical Co., Ltd. This fund raised will be used to continue to promote the commercialization of several blockbuster pediatric exclusive products and new 505(b)(2) drugs. By introducing strategic partners, Beimei Pharma can strengthen the construction of production base and the layout of the domestic marketing network and channels, thereby increasing its comprehensive competitive advantage in the field of pediatric drugs.

Since the beginning of 2023, Beimei Pharma has received frequent good news. The sales volume of 奥维平® , the first NMPA-approved Oseltamivir Phosphate for Suspension, increased dramatically and was successfully selected in the biding of the eighth batch of VBP.卫艾宁® (Esomeprazole magnesium for delayed release oral suspension) was officially approved in Feb. 2023, filling the gap in new dosage form and new specification in the Chinese PPI market. Meanwhile, Beimei Pharma has submitted the application of 4 new pediatric products to CDE. Currently, the total of 8 products are under CDE review and it’s expected that no less than 10 products will be approved in 2024. Lastly, Beimei Pharma successfully won the honorary titles of "National High-tech Enterprise" and "SRDI (Specialized-Refinement--Differential-Innovation)".

Beimei Pharmaceutical adheres to a strategy of "independent innovation and R&D + international license-in and cooperation" two-wheel drive, deeply cultivates pediatrics area, focuses on providing high-quality and full-range medicines for Chinese children, and contributes to the development of Chinese children's health.

Ms. Claire Wu, founder of Beimei Pharma, said

"We are very grateful to the investors for their high recognition of Beimei Pharma’s value. This round of financing is mainly strategic financing, which is particularly significant for the company. The funds will be used to accelerate the the landing of our self-developed products, to ensure the continuous investment in R&D, and to ensure the marketing approval of multiple products each year. I believe that the company will develop more smoothly with the strong support of Jiangsu Jinqiao Private Equity Fund Management Co., Ltd., Nanshan SEI Investment and Jiangsu Aosaikang Pharmaceutical Co., Ltd. Thanks again for the investors of this funding round."

Mr. Wanli Ma, General Manager of Jiangsu Jinqiao Private Equity Fund Management Co., Ltd., said.

"Due to the unique attributes of the pharmaceutical industry, companies need to achieve the perfect combination of technology and management, and need to accurately grasp market trends, timely follow up on R&D, and steadily promote sales in order to be invincible in the fierce market competition. Beimei Pharma focuses on the field of pediatric chemical prescription drugs, which was encouraged and supported by the national policies and has laid out more than 30 pediatric products, which cover different important clinical areas. Meanwhile, Beimei Pharma has an internationalized BD team, specialized R&D team and experienced sales team, and it has the core competitiveness for long-term development. We have full confidence in Beimei Pharma’s development in the field of children's medicines."

Danxiao Shen, Investment Director of Nanshan SEI Investment, said

"The supply of pediatric drug was in a shortage in the past was due to the constraints including difficulties in R&D and marketing, and low pricing. However, since 2016, the government has offered preferential policies in pediatric area, after which the consumption attributes of pediatric medical services have become increasingly prominent. The three-child policy and the promotion of refined childcare will lead to continuous strong demand of pediatric medical care, which is an inevitable path for the continuous adjustment of the demographic structure and the growing demand of the people. In China, there is a lack of specialized leading brands in the field of pediatric drugs. Beimei Pharma focuses on licensing-in and self-developing new pediatric prescription chemicals, with a pipeline covering respiratory drugs, antibiotics, digestive drugs, etc., all of which are children's prescription drugs with high clinical value. In addition, the product layout also covers disease fields with clinical gaps such as dermatology, otolaryngology, endocrine system and psychiatric system and Beimei Pharma is expected to become one of the leading pediatric drug companies in China."

Mr. Jingfei Ma, General Manager of Jiangsu Aosaikang Pharmaceutical Co., Ltd. , said

"Beimei Pharma is a startup based on and focusing on children's prescription drugs, of which the pipeline covers a series of children's specialty drugs. Beimei Pharma has introduced a number of global product portfolios suitable for pediatrics and is cooperating with a number of world's top technology platforms to co-develop innovative and differentiated children's drugs, which fulfills the mission and responsibility of meeting the unmet needs of children's medication and ensuring children's medication safety. Under the guidance of national policies for R&D project and establishment, review and approval, and market access of children's drugs, the development of new dosage forms and specifications that are more suitable for children, and drugs with better efficacy becomes the clinical value-oriented innovated direction for pharmaceutical companies. We believe that the children's drug market is still a Blue Ocean Market, and with the construction of market channels and the improvement of scientificity of clinical medicine, we believe that Beimei Pharma will be able to contribute more high-quality products to children's drug market in China."

About Jiangsu Jinqiao Private Equity Fund Management Co., Ltd.

Jiangsu Jinqiao Private Equity Fund Management Co., Ltd. establishes on September 29, 2021. It is an equity investment fund management organization that Lianyungang Industrial Investment Group initiates and establishes to optimize the integration of equity investment business. The company focuses on the investment of biomedicine, new materials, new energy, and other fields, and integrates industrial resources to help enterprises grow stronger and better.

About Shenzhen Nanshan SEI Investment Co.

Shenzhen Nanshan SEI Investment is a wholly state-owned limited liability company established by Shenzhen Nanshan District Government. The company is positioned as a strategic direct investment platform in Nanshan District, focusing on strategic emerging industries and future industries. The investment priorities include new-generation information technology, high-end equipment manufacturing, biomedicine, digital economy, and other advantageous industrial fields. The goal is to provide new momentum for the high-quality development of Nanshan’s economy .

About Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Jiangsu Aosaikang Pharmaceutical Co., Ltd., established in 2003, was originated from Nanjing Haiguang Institute of Applied Chemistry, which is one of the earliest private new drug research and development institutions in Jiangsu Province. The company's products cover four major therapeutic areas including digestion, anti-tumor, anti-infection, and chronic diseases. It has now developed into a high-tech enterprise integrating pharmaceutical research and development, manufacturing, marketing and sales, and has been awarded the honorary titles of "China’s Best Industrial Enterprise in Pharmaceutical R&D Product Line" and "China's Innovative Pharmaceutical Enterprise"for consecutive years.

About Shenzhen Beimei Pharmaceutical Co., Ltd.

Beimei pharmaceutical focuses on the field of pediatric prescription medicines, headquartered in Shenzhen, China, incorporating R&D, global licensing, manufacture, marketing and distribution, and has more than 30 pediatric products in its portfolio and pipeline, covering the respiratory system, anti-infection (antibacterial), nervous system, digestive system, endocrinology, ENT and other fields.

Beimei Pharmaceutical has established long-term partnerships with companies such as Hetero, Cipla, EMP, Deva, Dr Reddy, LTS, MedPharma, Synthon, NTC, etc., and completed over 100 million RMB series A and series B/B+ financing, which will further support Beimei to be a pioneer in Chinese pediatric field to meet the clinically unmet demand and provide Chinese pediatric patients with products that are with high-quality, good tasting and can be accurately administrated.

For more information, please visit our website at http://www.beimeiyaoye.com